Literature DB >> 24768993

A bacteriophage capsid protein provides a general amyloid interaction motif (GAIM) that binds and remodels misfolded protein assemblies.

Rajaraman Krishnan1, Haim Tsubery2, Ming Y Proschitsky2, Eva Asp2, Michal Lulu2, Sharon Gilead2, Myra Gartner2, Jonathan P Waltho3, Peter J Davis4, Andrea M Hounslow4, Daniel A Kirschner5, Hideyo Inouye5, David G Myszka6, Jason Wright2, Beka Solomon7, Richard A Fisher8.   

Abstract

Misfolded protein aggregates, characterized by a canonical amyloid fold, play a central role in the pathobiology of neurodegenerative diseases. Agents that bind and sequester neurotoxic intermediates of amyloid assembly, inhibit the assembly or promote the destabilization of such protein aggregates are in clinical testing. Here, we show that the gene 3 protein (g3p) of filamentous bacteriophage mediates potent generic binding to the amyloid fold. We have characterized the amyloid binding and conformational remodeling activities using an array of techniques, including X-ray fiber diffraction and NMR. The mechanism for g3p binding with amyloid appears to reflect its physiological role during infection of Escherichia coli, which is dependent on temperature-sensitive interdomain unfolding and cis-trans prolyl isomerization of g3p. In addition, a natural receptor for g3p, TolA-C, competitively interferes with Aβ binding to g3p. NMR studies show that g3p binding to Aβ fibers is predominantly through middle and C-terminal residues of the Aβ subunit, indicating β strand-g3p interactions. A recombinant bivalent g3p molecule, an immunoglobulin Fc (Ig) fusion of the two N-terminal g3p domains, (1) potently binds Aβ fibers (fAβ) (KD=9.4nM); (2); blocks fAβ assembly (IC50~50nM) and (3) dissociates fAβ (EC50=40-100nM). The binding of g3p to misfolded protein assemblies is generic, and amyloid-targeted activities can be demonstrated using other misfolded protein systems. Taken together, our studies show that g3p(N1N2) acts as a general amyloid interaction motif.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Ig fusion; amyloid; amyloid remodeling; gene 3 protein

Mesh:

Substances:

Year:  2014        PMID: 24768993     DOI: 10.1016/j.jmb.2014.04.015

Source DB:  PubMed          Journal:  J Mol Biol        ISSN: 0022-2836            Impact factor:   5.469


  14 in total

Review 1.  Emerging disease-modifying strategies targeting α-synuclein for the treatment of Parkinson's disease.

Authors:  Darren M O'Hara; Suneil K Kalia; Lorraine V Kalia
Journal:  Br J Pharmacol       Date:  2018-06-03       Impact factor: 8.739

Review 2.  Designer protein disaggregases to counter neurodegenerative disease.

Authors:  James Shorter
Journal:  Curr Opin Genet Dev       Date:  2017-02-14       Impact factor: 5.578

Review 3.  General Principles Underpinning Amyloid Structure.

Authors:  Alexander I P Taylor; Rosemary A Staniforth
Journal:  Front Neurosci       Date:  2022-06-02       Impact factor: 5.152

Review 4.  Postmortem Studies of Fetal Grafts in Parkinson's Disease: What Lessons Have We Learned?

Authors:  Jia-Yi Li; Wen Li
Journal:  Front Cell Dev Biol       Date:  2021-05-13

Review 5.  A Dormant Microbial Component in the Development of Preeclampsia.

Authors:  Douglas B Kell; Louise C Kenny
Journal:  Front Med (Lausanne)       Date:  2016-11-29

6.  A Peptide-Fc Opsonin with Pan-Amyloid Reactivity.

Authors:  James S Foster; Angela D Williams; Sallie Macy; Tina Richey; Alan Stuckey; Daniel Craig Wooliver; Richa Koul-Tiwari; Emily B Martin; Stephen J Kennel; Jonathan S Wall
Journal:  Front Immunol       Date:  2017-09-04       Impact factor: 7.561

Review 7.  New Perspectives on Roles of Alpha-Synuclein in Parkinson's Disease.

Authors:  Guoxin Zhang; Yun Xia; Fang Wan; Kai Ma; Xingfang Guo; Liang Kou; Sijia Yin; Chao Han; Ling Liu; Jinsha Huang; Nian Xiong; Tao Wang
Journal:  Front Aging Neurosci       Date:  2018-11-22       Impact factor: 5.750

Review 8.  To What Extent Are the Terminal Stages of Sepsis, Septic Shock, Systemic Inflammatory Response Syndrome, and Multiple Organ Dysfunction Syndrome Actually Driven by a Prion/Amyloid Form of Fibrin?

Authors:  Douglas B Kell; Etheresia Pretorius
Journal:  Semin Thromb Hemost       Date:  2017-08-04       Impact factor: 4.180

9.  NPT088 reduces both amyloid-β and tau pathologies in transgenic mice.

Authors:  Jonathan M Levenson; Sally Schroeter; Jenna C Carroll; Valerie Cullen; Eva Asp; Ming Proschitsky; Charlotte H-Y Chung; Sharon Gilead; Muhammad Nadeem; Hemraj B Dodiya; Shadiyat Shoaga; Elliott J Mufson; Haim Tsubery; Rajaraman Krishnan; Jason Wright; Beka Solomon; Richard Fisher; Kimberley S Gannon
Journal:  Alzheimers Dement (N Y)       Date:  2016-07-14

Review 10.  Passive immunotherapies targeting Aβ and tau in Alzheimer's disease.

Authors:  Steven S Plotkin; Neil R Cashman
Journal:  Neurobiol Dis       Date:  2020-07-16       Impact factor: 7.046

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.